| Price | 52.50p on 27-01-2026 at 16:25:23 |
|---|---|
| Change | -1.50p -2.78% |
| Buy | 54.00p |
| Sell | 51.00p |
| Last Trade: | Buy 291.00 at 53.50p |
| Day's Volume: | 1,126,226 |
| Last Close: | 54.00p |
| Open: | 54.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 52.50p - 54.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £229.76m |
| VWAP: | 52.97557p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 291 | 53.50p | Ordinary |
16:25:21 - 27-Jan-26 |
| Buy* | 2,000 | 53.4973p | Ordinary |
16:23:15 - 27-Jan-26 |
| Buy* | 201 | 53.1137p | Ordinary |
16:22:38 - 27-Jan-26 |
| Buy* | 1,861 | 53.50p | Ordinary |
16:21:26 - 27-Jan-26 |
| Buy* | 4,104 | 53.111p | Ordinary |
16:19:39 - 27-Jan-26 |
| Buy* | 44,437 | 53.95p | Ordinary |
16:17:36 - 27-Jan-26 |
| Buy* | 3,000 | 53.4373p | Ordinary |
16:16:43 - 27-Jan-26 |
| Buy* | 376 | 53.4373p | Ordinary |
16:14:22 - 27-Jan-26 |
| Buy* | 3 | 53.4373p | Ordinary |
16:13:55 - 27-Jan-26 |
| Buy* | 208 | 53.4373p | Ordinary |
16:12:33 - 27-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |
| 20th Jan 2026 7:00 am | RNS | Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
